Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Jul

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma

Women Aged 65 Plus Still at Heightened Risk of HPV-Related Cervical Cancer

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Optimizing the CAR to the Disease in B-Cell Malignancies

Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk